Welcome to our dedicated page for COGNITION THERAPEUTICS SEC filings (Ticker: CGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognition Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing zervimesine for neurodegenerative diseases. Its Form 8-K reports cover financial results, Regulation FD presentations, clinical-development announcements, FDA meeting disclosures, and material agreements, including an at-the-market common-stock sales arrangement.
Proxy materials disclose annual meeting and stockholder voting matters, while registration and current-report disclosures identify the company’s Delaware corporate status, emerging growth company reporting status, and Nasdaq-listed common stock. The filings also provide formal records of capital-structure activity, governance processes, and risk areas associated with clinical research, regulatory review, grant funding, and the financing needs of a development-stage biotechnology company.
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for age‑related degenerative diseases of the central nervous system and retina. Its lead candidate, zervimesine (CT1812), targets toxic protein oligomers implicated in Alzheimer’s disease, dementia with Lewy bodies and dry age‑related macular degeneration.
Zervimesine has shown cognitive and functional benefits in multiple Phase 1 and 2 studies and holds FDA Fast Track designation for Alzheimer’s disease. The pipeline is heavily supported by non‑dilutive funding, with about $171 million in cumulative grants, including major awards from the National Institute on Aging.
The company reports 10 issued U.S. patents and broad international filings around zervimesine, with core composition‑of‑matter protection projected into 2035 and potential extensions. As of March 1, 2026, it had 14 employees and continued to progress late‑stage trials and regulatory interactions in Alzheimer’s and Lewy body dementia.
Cognition Therapeutics reported improved 2025 results with a smaller loss and stronger balance sheet while advancing its neurology pipeline. For the year ended December 31, 2025, the company recorded a net loss of $23.5 million, or $(0.32) per share, compared with a net loss of $34.0 million, or $(0.86) per share in 2024.
Research and development expenses fell to $37.2 million from $41.7 million, and general and administrative expenses declined to $10.6 million from $12.3 million, reflecting lower clinical and stock-based compensation costs. Grant income increased to $23.4 million.
Cash, cash equivalents, and restricted cash were $37.0 million as of December 31, 2025, with remaining obligated grant funds of $35.7 million. The company estimates its cash will fund operations and capital spending through the second quarter of 2027. Clinically, it completed enrollment in the Phase 2 START Alzheimer’s study, reported strong Phase 2 SHIMMER data in DLB, launched an expanded access program for DLB, and is planning a mid-2026 FDA Division of Psychiatry meeting to align on a registrational path for zervimesine in DLB psychosis.
Cognition Therapeutics reported that it is advancing development of its oral drug zervimesine (CT1812) as a potential treatment for dementia with Lewy bodies (DLB) psychosis, a condition affecting as many as 75% of DLB patients and with no currently approved therapies.
The company’s plan follows final minutes from an FDA Type C meeting held on January 21, 2026 and is based on Phase 2 SHIMMER data showing zervimesine slowed decline on the 12‑item neuropsychiatric inventory by 86% versus placebo. The next DLB study is intended as a registrational trial focused on neuropsychiatric and behavioral symptoms, randomizing patients to 100 mg zervimesine or placebo with an open‑label extension.
Cognition expects to meet with the FDA Division of Psychiatry by midyear 2026 to discuss the DLB psychosis program. Zervimesine has been generally well tolerated in clinical studies and is also being evaluated in Alzheimer’s disease and other neurodegenerative indications with substantial grant support from the National Institute on Aging.
Cognition Therapeutics CEO Lisa Ricciardi reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 5,850 shares of common stock at $1.12 per share to cover tax obligations. After this, she directly owns 1,706,676 shares, plus 38,851 shares held indirectly by her spouse.
COGNITION THERAPEUTICS INC Chief Financial Officer John Brendan Doyle reported a tax-related share disposition. On the vesting of restricted stock units, the issuer withheld 1,560 shares of common stock at $1.12 per share to cover tax obligations, leaving Doyle with 617,509 directly owned shares after the transaction.
COGNITION THERAPEUTICS INC Chief Medical Officer Anthony Caggiano reported a tax-related share disposition. On 2026-02-15, he had 4,680 shares of common stock withheld at $1.12 per share to cover tax obligations from vesting restricted stock units. After this tax-withholding transaction, he directly owned 864,906 shares of common stock.
Cognition Therapeutics CEO and President Lisa Ricciardi reported equity compensation and related tax withholding transactions in company stock. On February 3, 2026, she acquired 800,000 RSU-based shares of common stock at $0.00 per share, reflecting a stock award.
On the same day, the company withheld 26,036 shares at $1.12 to cover taxes tied to RSU vesting, and on February 4, 2026 withheld another 51,704 shares at $1.03 for the same purpose. After these transactions, she directly beneficially owned 1,712,526 shares, with an additional 38,851 shares held indirectly by her spouse.
Cognition Therapeutics (CGTX) Chief Financial Officer John Brendan Doyle reported equity compensation and related tax withholding transactions. On February 3, 2026, he acquired 200,000 shares of Common Stock at $0.00 per share, representing restricted stock units (RSUs), increasing his direct holdings to 645,990 shares.
On February 4, 2026, 26,921 shares of Common Stock were withheld at $1.03 per share to cover tax obligations tied to RSU vesting, leaving Doyle with 619,069 directly owned shares of Cognition Therapeutics Common Stock.
Cognition Therapeutics Chief Medical Officer Anthony Caggiano reported equity compensation and related tax withholding in company stock. On 02/03/2026, he acquired 400,000 shares of Common Stock at $0.00 per share, representing settlement of restricted stock units, each equal to one share of Common Stock upon vesting.
On the same date, 11,488 shares were withheld at $1.12 per share, and on 02/04/2026 a further 26,919 shares were withheld at $1.03 per share, to cover tax obligations tied to the RSU vesting. After these transactions, Caggiano directly owned 869,586 shares of Cognition Therapeutics Common Stock.
Cognition Therapeutics, Inc. filed a current report to note that it has issued a press release about completing a Tye C meeting with the U.S. Food and Drug Administration for its drug candidate zervimesine in dementia with Lewy bodies. The company is furnishing this press release as an exhibit to the report, providing investors with an official update on this regulatory interaction.